search
Back to results

Oligogenic Determinism of Colorectal Cancer (DOCC)

Primary Purpose

Cancer

Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Blood drawn
Sponsored by
University Hospital, Rouen
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Cancer focused on measuring Colo-Rectal Cancer

Eligibility Criteria

18 Years - 61 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • colorectal cancer (CRC) in two first degree relatives, one being diagnosed before 61 years of age
  • CRC diagnosed before 51 years of age or advanced colorectal adenoma before 41 years of age
  • multiple primary CRCs in the same individual, the first being diagnosed before 61 years of age.

Exclusion Criteria:

  • Lynch syndrome,
  • adenomatous polyposis defined by more than 10 adenomas histologically proved,
  • hamartomatous polyposis defined by one hamartoma histologically proved,
  • absence of informed consent.

Sites / Locations

  • Centre François Baclesse
  • CHU de Dijon
  • CHU de Grenoble
  • CHRU de Lille
  • CHU de Montpellier
  • CLCC Val d'Aurelle
  • CH de Niort
  • Institut Curie
  • Hôpital Européen Georges Pompidou
  • Centre Eugène Marquis
  • CHU de Rennes
  • UHRouen
  • CHU de Saint-Etienne
  • CHU de Toulouse
  • Institut Claudius Regaud
  • Institut Gustave Roussy

Arms of the Study

Arm 1

Arm Type

No Intervention

Arm Label

Patient

Arm Description

Blood sample for patient included

Outcomes

Primary Outcome Measures

genetic variation assessment

Secondary Outcome Measures

Full Information

First Posted
January 27, 2010
Last Updated
October 15, 2013
Sponsor
University Hospital, Rouen
search

1. Study Identification

Unique Protocol Identification Number
NCT01057953
Brief Title
Oligogenic Determinism of Colorectal Cancer
Acronym
DOCC
Official Title
Oligogenic Determinism of Colorectal Cancer
Study Type
Interventional

2. Study Status

Record Verification Date
October 2013
Overall Recruitment Status
Completed
Study Start Date
January 2010 (undefined)
Primary Completion Date
January 2013 (Actual)
Study Completion Date
January 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Rouen

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The majority of the clinical situations suggestive of an increased genetic risk for colorectal cancer (CRC) are not explained by a simple monogenic model. Our working hypothesis is that a fraction of clinical conditions suggestive of an increased genetic risk for CRC (familial aggregation, early age of tumour onset, development of multiple primary CRC) is due to the combination of a limited number of genetic variations, each conferring a moderate risk for CRC, but whose combination results into high risk. This study, which will be both retrospective and prospective, is an association study that will compare frequencies of selected genetic variations, alone or in combination, between patients (cases) whose clinical presentation is suggestive of an increased genetic risk but who do not present a known Mendelian form of CRC, and controls, in order to assess associations of these variations with non-Mendelian genetic forms of CRC. The inclusion criteria will be: CRC in two first degree relatives, one being diagnosed before 61 years of age; or CRC diagnosed before 51 years of age or advanced colorectal adenoma before 41 years of age; or multiple primary CRCs in the same individual, the first being diagnosed before 61 years of age The exclusion criteria will be: Lynch syndrome, adenomatous polyposis and hamartomatous polyposis. The genetic variations which will be analyzed will include (i) SNPs detected by GWAS and associated to CRC. (ii) Risk factors corresponding to functional polymorphisms within candidate genes. (iii) Imbalance of the TGFbR1 allelic expression. Sample sizes were calculated to obtain 80% power for an odds ratio of 2.5 since the aim of this study is to determine genetic variations conferring a moderate risk. In order to cover all these possibilities and to have reasonable even for the genetic variations with low frequency below 0.03 or high frequency above 0.90, the target sample size was set at 700 cases and 350 controls. The recruitment of patients will be performed at the national level by the cancer genetics departments ensuring a correct evaluation of the personal and familial history and the French molecular diagnosis laboratories network ensuring in routine the analysis of the main genes involved in CRC. The control population will be composed of healthy subjects of Caucasian origin between 45 and 60 years of age, without personal or familial history among their first-degree relatives of colorectal tumours. Demonstration that the combination of a limited number of genetic variations, each conferring a moderate risk for CRC, results into high risk would allow to base, in selected families, the evaluation of risk in relatives and indication of colonoscopy on the analysis of gene variants the combination of which would confer a high risk. This study will confirm or invalidate the contribution of aTGFbR1 allelic expression imbalance in the determinism of early-onset CRC and familial aggregation of CRC. The demonstration of the involvement in CRC genetic variations with strong effect of specific combinations should be of interest for our general understanding of the molecular basis of CRC.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cancer
Keywords
Colo-Rectal Cancer

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
1550 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Patient
Arm Type
No Intervention
Arm Description
Blood sample for patient included
Intervention Type
Genetic
Intervention Name(s)
Blood drawn
Intervention Description
Blood drawn for patient
Primary Outcome Measure Information:
Title
genetic variation assessment
Time Frame
once

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
61 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: colorectal cancer (CRC) in two first degree relatives, one being diagnosed before 61 years of age CRC diagnosed before 51 years of age or advanced colorectal adenoma before 41 years of age multiple primary CRCs in the same individual, the first being diagnosed before 61 years of age. Exclusion Criteria: Lynch syndrome, adenomatous polyposis defined by more than 10 adenomas histologically proved, hamartomatous polyposis defined by one hamartoma histologically proved, absence of informed consent.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Thierry FREBOURG, Pr
Organizational Affiliation
CHU de Rouen
Official's Role
Principal Investigator
Facility Information:
Facility Name
Centre François Baclesse
City
Caen
ZIP/Postal Code
14000
Country
France
Facility Name
CHU de Dijon
City
Dijon
Country
France
Facility Name
CHU de Grenoble
City
Grenoble
Country
France
Facility Name
CHRU de Lille
City
Lille
Country
France
Facility Name
CHU de Montpellier
City
Montpellier
Country
France
Facility Name
CLCC Val d'Aurelle
City
Montpellier
Country
France
Facility Name
CH de Niort
City
Niort
Country
France
Facility Name
Institut Curie
City
Paris
ZIP/Postal Code
75005
Country
France
Facility Name
Hôpital Européen Georges Pompidou
City
Paris
Country
France
Facility Name
Centre Eugène Marquis
City
Rennes
ZIP/Postal Code
35000
Country
France
Facility Name
CHU de Rennes
City
Rennes
Country
France
Facility Name
UHRouen
City
Rouen
ZIP/Postal Code
76031
Country
France
Facility Name
CHU de Saint-Etienne
City
Saint-Etienne
Country
France
Facility Name
CHU de Toulouse
City
Toulouse
Country
France
Facility Name
Institut Claudius Regaud
City
Toulouse
Country
France
Facility Name
Institut Gustave Roussy
City
Villejuif
ZIP/Postal Code
94800
Country
France

12. IPD Sharing Statement

Learn more about this trial

Oligogenic Determinism of Colorectal Cancer

We'll reach out to this number within 24 hrs